250214-44-9

Basic information

• Product Name: FESOTERODINE
• Synonyms: FESOTERODINE;2-Methylpropanoic acid 2-[3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-(hydroxymethyl)phenyl ester
• CAS NO: 250214-44-9
• Molecular Formula: C26H37NO3
• Molecular Weight: 411.582
• Mol File: 250214-44-9.mol
• Article Data: 30

Chemical Properties

• Boiling Point: 518.9 °C at 760 mmHg
• Flash Point: 267.6 °C
• Appearance: /
• Density: 1.043
• PKA: 14.27±0.10(Predicted)
• CAS DataBase Reference: FESOTERODINE(CAS DataBase Reference)
• NIST Chemistry Reference: FESOTERODINE(250214-44-9)
• EPA Substance Registry System: FESOTERODINE(250214-44-9)

Safety Data

• Hazardous Substances Data: 250214-44-9(Hazardous Substances Data)

Usage

General Description

Fesoterodine is a medication used to treat overactive bladder symptoms such as frequent urination, urgent urination, and urinary incontinence. It works by relaxing the bladder muscles and increasing the bladder capacity, thereby reducing the symptoms of overactive bladder. Fesoterodine belongs to a class of drugs called anticholinergics, which block the action of a certain natural substance in the body that causes the bladder muscles to contract. By blocking this action, fesoterodine helps to relieve the symptoms of overactive bladder and improve urinary control. It is typically taken orally in the form of extended-release tablets and should be used as directed by a healthcare professional. Common side effects of fesoterodine may include dry mouth, constipation, and blurred vision. It is important to discuss the potential benefits and risks of fesoterodine with a doctor before starting this medication.

Upstream product

• 140-10-3 (E)-3-phenylacrylic acid 
• 156755-35-0 methyl 4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]benzoate 
• 950773-38-3 R-(-)-[3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl]diisopropylamine 
• 106-41-2 4-bromo-phenol 
• 156755-23-6 6-bromo-4-phenyl-3,4-dihydro-2H-chromen-2-one 
• 156755-37-2 {4-(benzyloxy)-3-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]phenyl}methanol 
• 156755-24-7 methyl 3-[2-(benzyloxy)-5-bromophenyl]-3-phenylpropanoate 
• 250214-37-0 (+/-)-toluene-4-sulphonic acid 3-(2-benzyloxy-5-bromophenyl)-3-phenylpropyl ester 
• 156755-33-8 (R)-4-(benzyloxy)-3-(3-(diisopropylamino)-1-phenylpropyl)benzoic acid hydrochloride 
• 1135493-18-3 C₂₀H₁₈O₈*C₂₈H₃₄BrNO 
• 21087-29-6 trans-3-phenylprop-2-enyl chloride 
• 173948-30-6 (E)-N,N-diisopropyl-3-phenylprop-2-en-1-amine 
• 250214-39-2 (-)-N,N-diisopropyl-3-(2-benzyloxy-5-hydroxymethylphenyl)-3-phenylpropylamine 
• 1349883-68-6 (+/-)-4-bromo-2-(3-hydroxy-1-phenylpropyl)phenol 

Downstream Products

• 286930-03-8 2-[(1R)-3-(dipropan-2-ylamino)-1-phenylpropyl]-4-(hydroxymethyl)phenyl 2-methylpropanoate fumarate 
• 200801-70-3 RS-N,N-diisopropyl-3-(2-hydroxy-5-(hydroxymethyl)phenyl)-3-phenylpropylamine 

Relevant articles and documents

PROCESS FOR THE PREPARATION OF OPTICALLY PURE FESOTERODINE DERIVATIVES

3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, can be produced by treating a compound of formula (II) with a chiral alcohol to yield the diastereomeric esters of formula (IV) and (IV′), which can be further transformed into a compound of formula (I), or an enantiomer, solvate or salt thereof, wherein R1 is C1-C8 alkyl; and R2 and R3, independently of one another, represent H or C1-C6 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound.

PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 3,3-DIPHENYLPROPYLAMINES

The invention relates to a process for obtaining 3,3-diphenylpropylamines of general formula (I), particularly Fesoterodine, as well as their enantiomers, solvates and salts, comprising treating a compound of formula (II) with a chiral alcohol to yield the diastereomeric esters of formula (IV) and (IV'), which can be further transformed into a compound of formula (I), or an enantiomer, solvate or salt thereof, wherein R1 is C1-C8 alkyl; and R2 and R3, independently of one another, represent H or C1-C6 alkyl, or together form a ring of 3 to 7 members with the nitrogen to which they are bound.

PROCESS FOR THE PREPARATION OF MUSCARINIC RECEPTOR ANTAGONIST

The present invention relates to novel and improved processes for the preparation of (r)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenylisobutyrate represented by the following structural formula-1 and its pharmaceutically acceptable salts thereof.